Ocuphire Pharma (OCUP) Receives a Buy from JonesTrading

In a report released today, Sean Kim PhD from JonesTrading reiterated a Buy rating on Ocuphire Pharma (OCUPResearch Report), with a price target of $16.00. The company’s shares opened today at $3.00.

According to TipRanks, Kim PhD is a 3-star analyst with an average return of 11.1% and a 55.56% success rate. Kim PhD covers the Healthcare sector, focusing on stocks such as Ocuphire Pharma, Concert Pharma, and Satsuma Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocuphire Pharma with a $20.75 average price target, which is a 591.67% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.

See the top stocks recommended by analysts >>

OCUP market cap is currently $78.23M and has a P/E ratio of -3.20.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Read More on OCUP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed